Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer

• Published in: International journal of oncology Vol. 38; no. 1; p. 13
• Main Authors: Azuma, Haruhito, Inamoto, Teruo, Ibuki, Naokazu, Ubai, Takanobu, Kotake, Yatsugu, Takahara, Kiyoshi, Kiyama, Satoshi, Nomi, Hayahito, Uehara, Hiroshi, Komura, Kazumasa, Yamamoto, Kazuhiro, Narumi, Yoshihumi, Katsuoka, Yoji
• Format: Journal Article
• Language: English
• Published: Greece 01.01.2011
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Catheterization - methods; Cisplatin - administration & dosage; Combined Modality Therapy; Cystectomy; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Male; Neoplasm Staging; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy
• ISSN: 1019-6439; 1791-2423
• DOI: 10.3892/ijo_00000819

In this study, we investigated the novel bladder preservation therapy, the balloon-occluded arterial infusion (BOAI) of cisplatin/gemcitabine, concomitantly with hemodialysis, along with concurrent irradiation [the 'Osaka Medical College (OMC)-regimen'] in patients >70 years of age with muscle-invasive bladder cancer. Eighty-three such patients were assigned to receive either the OMC-regimen (n=56) or cystectomy (n=27). The OMC-regimen patients who failed to achieve complete response (CR) underwent cystectomy, or secondary BOAI with gemcitabine (1600 mg). The OMC-regimen, which delivers an extremely high concentration of anti-cancer agent to the tumor site without systemic adverse effects, yielded CR in >90% (39/43) of patients with locally invasive tumors [70% (39/56) of all patients including those with T4 and N+ disease]. None of the CR patients showed recurrence after a mean follow-up of 162 (range, 35-683) weeks, and 2 patients died of unrelated causes. The 5- and 12-year overall survival rates were 92.7 and 69.5% (vs. 59.6 and 20.9% for cystectomy; P<0.0092), respectively, although the median age in the OMC-regimen group was significantly greater than that in the cystectomy group (median, 77; range, 70-98; vs. 74; 70-79; p<0.0001). No patients suffered grade III or more severe toxicities. The oldest patient, aged 98 years, successfully completed this therapy. The OMC-regimen is a useful bladder preservation strategy for elderly patients with locally invasive bladder cancer, not only for those for whom cystectomy has been indicated, but also for patients whose condition is not amenable to curative treatment and for whom palliation would otherwise seem the only option.